Drug developer Scholar Rock's Q3 net loss widens

Scholar Rock Holding

14/11/2025 12:08

Overview

Scholar Rock Q3 net loss widens to $102.2 mln, no revenue recorded

Operating expenses increased due to apitegromab launch readiness

Company expects cash reserves to fund operations into 2027

Outlook

Scholar Rock anticipates U.S. launch of apitegromab in 2026

Company reserves commercial capacity for apitegromab starting Q1 2026

Scholar Rock expects to start SRK-439 dosing in Q4 2025

Result Drivers

Research and development expense was $50.5 million, including $5.5 million in stock-based compensation, for the quarter ended September 30, 2025, compared to $48.7 million, including $4.4 million in stock-based compensation, for the quarter ended September 30, 2024

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q3 EPS
-$0.90
Q3 Net Income
-$102.22 mln
Q3 Income from Operations
-$103.55 mln
Q3 Operating Expenses
$103.55 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 13 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Scholar Rock Holding Corp is $45.00, about 33.2% above its November 13 closing price of $30.07

Press Release: ID:nBw379hG4a

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)